Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Immunotherapy, Adoptive"" wg kryterium: Temat


Tytuł :
A novel chimeric antigen receptor redirecting T-cell specificity towards CD26 cancer cells.
Autorzy :
Zhou S; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Li W; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Xiao Y; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Zhu X; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Zhong Z; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Li Q; Department of Hematology, Wuhan No.1 Hospital, Wuhan, 430022, China.
Cheng F; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Zou P; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
You Y; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. .
Zhu X; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. .
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2021 Jan; Vol. 35 (1), pp. 119-129. Date of Electronic Publication: 2020 Apr 21.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Immunotherapy, Adoptive*/adverse effects
Immunotherapy, Adoptive*/methods
Dipeptidyl Peptidase 4/*immunology
Receptors, Antigen, T-Cell/*immunology
Receptors, Chimeric Antigen/*immunology
T-Cell Antigen Receptor Specificity/*immunology
T-Lymphocytes/*immunology
T-Lymphocytes/*metabolism
Animals ; Biomarkers ; Cell Line, Tumor ; Cytotoxicity, Immunologic ; Disease Models, Animal ; Gene Expression Profiling ; Humans ; Immunophenotyping ; Mice ; Neoplasms/immunology ; Neoplasms/therapy ; Receptors, Antigen, T-Cell/genetics ; Receptors, Chimeric Antigen/genetics ; T-Cell Antigen Receptor Specificity/genetics ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
CAR-T in solid tumors: Blazing a new trail through the brambles.
Autorzy :
Guo F; Cancer Center, The First Hospital of Jilin University, Changchun 130021, China.
Cui J; Cancer Center, The First Hospital of Jilin University, Changchun 130021, China. Electronic address: .
Pokaż więcej
Źródło :
Life sciences [Life Sci] 2020 Nov 01; Vol. 260, pp. 118300. Date of Electronic Publication: 2020 Aug 20.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Immunotherapy, Adoptive*/methods
Immunotherapy, Adoptive*/trends
Receptors, Chimeric Antigen*
Neoplasms/*therapy
Antigens, Neoplasm/immunology ; Humans ; Immune Tolerance ; Tumor Microenvironment/physiology
Czasopismo naukowe
Tytuł :
CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression.
Autorzy :
Fousek K; Interdepartmental Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, TX, USA.; Center for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston, TX, USA.; Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.; Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Watanabe J; Division of Hematology, Oncology and Bone Marrow Transplantation, Children's Hospital Los Angeles, Los Angeles, CA, United States.
Joseph SK; Center for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston, TX, USA.; Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.; Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
George A; Division of Hematology, Oncology and Bone Marrow Transplantation, Children's Hospital Los Angeles, Los Angeles, CA, United States.
An X; Department of Chemical and Biomolecular Engineering, University of Houston, Houston, TX, USA.
Byrd TT; Interdepartmental Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, TX, USA.; Center for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston, TX, USA.; Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.; Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Morris JS; Interdepartmental Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, TX, USA.; Center for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston, TX, USA.; Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.; Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Luong A; Division of Hematology, Oncology and Bone Marrow Transplantation, Children's Hospital Los Angeles, Los Angeles, CA, United States.; University of Southern California Keck School of Medicine, Los Angeles, CA, USA.
Martínez-Paniagua MA; Department of Chemical and Biomolecular Engineering, University of Houston, Houston, TX, USA.
Sanber K; Center for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston, TX, USA.; Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.; Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Navai SA; Center for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston, TX, USA.; Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.; Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Gad AZ; Interdepartmental Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, TX, USA.; Center for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston, TX, USA.; Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.; Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Salsman VS; Center for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston, TX, USA.; Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.; Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Mathew PR; Center for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston, TX, USA.; Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.; Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Kim HN; Division of Hematology, Oncology and Bone Marrow Transplantation, Children's Hospital Los Angeles, Los Angeles, CA, United States.; University of Southern California Keck School of Medicine, Los Angeles, CA, USA.
Wagner DL; Center for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston, TX, USA.; Institute of Medical Immunology, Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, Berlin, Germany.; Berlin Institute of Health-Center for Regenerative Therapies (B-CRT), Charité-Universitätsmedizin Berlin, Berlin, Germany.
Brunetti L; Center for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston, TX, USA.
Jang A; Center for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston, TX, USA.
Baker ML; National Center for Macromolecular Imaging and Verna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX, USA.
Varadarajan N; Department of Chemical and Biomolecular Engineering, University of Houston, Houston, TX, USA.
Hegde M; Center for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston, TX, USA.; Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.; Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Kim YM; Division of Hematology, Oncology and Bone Marrow Transplantation, Children's Hospital Los Angeles, Los Angeles, CA, United States.; University of Southern California Keck School of Medicine, Los Angeles, CA, USA.
Heisterkamp N; Division of Hematology, Oncology and Bone Marrow Transplantation, Children's Hospital Los Angeles, Los Angeles, CA, United States.; University of Southern California Keck School of Medicine, Los Angeles, CA, USA.; Department of Systems Biology, Beckman Research Institute City of Hope, Duarte, CA, United States.
Abdel-Azim H; Division of Hematology, Oncology and Bone Marrow Transplantation, Children's Hospital Los Angeles, Los Angeles, CA, United States. .; University of Southern California Keck School of Medicine, Los Angeles, CA, USA. .
Ahmed N; Interdepartmental Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, TX, USA. .; Center for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston, TX, USA. .; Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA. .; Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA. .
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2021 Jan; Vol. 35 (1), pp. 75-89. Date of Electronic Publication: 2020 Mar 24.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :
Immunotherapy, Adoptive*/methods
Antigens, CD19/*immunology
Leukemia, B-Cell/*immunology
Leukemia, B-Cell/*metabolism
Receptors, Antigen, T-Cell/*immunology
Receptors, Chimeric Antigen/*immunology
T-Lymphocytes/*immunology
T-Lymphocytes/*metabolism
Animals ; Antigens, CD19/chemistry ; Antigens, Neoplasm ; Biomarkers ; Cell Line, Tumor ; Cytokines/metabolism ; Cytotoxicity, Immunologic ; Disease Models, Animal ; Gene Expression ; Humans ; Leukemia, B-Cell/genetics ; Leukemia, B-Cell/therapy ; Mice, Transgenic ; Protein Binding ; Receptors, Antigen, T-Cell/metabolism ; Receptors, Chimeric Antigen/genetics ; Receptors, Chimeric Antigen/metabolism ; Structure-Activity Relationship ; Transduction, Genetic ; Transgenes ; Treatment Outcome ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Designed Ankyrin Repeat Protein (DARPin) to target chimeric antigen receptor (CAR)-redirected T cells towards CD4 cell reservoir.
Autorzy :
Patasic L; Host-Pathogen Interactions, Paul-Ehrlich-Institut, Langen, Germany.
Seifried J; Host-Pathogen Interactions, Paul-Ehrlich-Institut, Langen, Germany. .; Department for Infectious Disease Epidemiology, Robert Koch-Institute, Berlin, Germany. .
Bezler V; Regensburg Center for Interventional Immunology (RCI), Department of Genetic Immunotherapy, University Hospital Regensburg, Regensburg, Germany.
Kaljanac M; Regensburg Center for Interventional Immunology (RCI), Department of Genetic Immunotherapy, University Hospital Regensburg, Regensburg, Germany.
Schneider IC; Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut, Langen, Germany.
Schmitz H; Host-Pathogen Interactions, Paul-Ehrlich-Institut, Langen, Germany.
Tondera C; Host-Pathogen Interactions, Paul-Ehrlich-Institut, Langen, Germany.
Hartmann J; Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut, Langen, Germany.
Hombach A; Center for Molecular Medicine Cologne, University of Cologne, and Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany.
Buchholz CJ; Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut, Langen, Germany.
Abken H; Center for Molecular Medicine Cologne, University of Cologne, and Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany.; Regensburg Center for Interventional Immunology (RCI), Department of Genetic Immunotherapy, University Hospital Regensburg, Regensburg, Germany.
König R; Host-Pathogen Interactions, Paul-Ehrlich-Institut, Langen, Germany.; German Center for Infection Research (DZIF), Langen, Germany.; Immunity and Pathogenesis Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Cichutek K; Host-Pathogen Interactions, Paul-Ehrlich-Institut, Langen, Germany. .; Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut, Langen, Germany. .; German Center for Infection Research (DZIF), Langen, Germany. .
Pokaż więcej
Źródło :
Medical microbiology and immunology [Med Microbiol Immunol] 2020 Dec; Vol. 209 (6), pp. 681-691. Date of Electronic Publication: 2020 Sep 12.
Typ publikacji :
Journal Article
MeSH Terms :
Ankyrin Repeat*
Immunotherapy, Adoptive*
CD4-Positive T-Lymphocytes/*virology
HIV/*isolation & purification
HIV Infections/*immunology
Lymphocyte Depletion/*methods
Peptides/*pharmacology
CD4-Positive T-Lymphocytes/drug effects ; CD4-Positive T-Lymphocytes/immunology ; Dose-Response Relationship, Immunologic ; Drug Evaluation, Preclinical ; Gammaretrovirus/genetics ; Genetic Vectors/genetics ; HEK293 Cells ; HIV Infections/virology ; Humans ; Lymphocyte Activation ; Peptides/chemistry ; Single-Chain Antibodies/immunology ; Transduction, Genetic
Czasopismo naukowe
Tytuł :
[Quality assessment of CAR T-cell activity: Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Autorzy :
Duléry R; AP-HP, hôpital Saint-Antoine, Sorbonne Université, service d'hématologie clinique et thérapie cellulaire, 184, rue du Faubourg-Saint-Antoine, 75012 Paris, France. Electronic address: .
Lacassagne MN; CHU Amiens Sud, unité de thérapie cellulaire, 1, rue du Professeur Christian-Cabrol, 80054 Amiens, France.
Giraud C; CHU de Poitiers, service d'oncologie hématologique et thérapie cellulaire et EFS Nouvelle Aquitaine, unité d'aphérèse et thérapie cellulaire, 2, rue de la Milétrie, 86021 Poitiers, France.
Ader V; EFS Occitanie, institut universitaire du cancer Toulouse Oncopole, unité d'aphérèse, avenue de Grande-Bretagne, 31300 Toulouse, France.
Beaumont JL; CHU Henri Mondor, unité d'aphérèses thérapeutiques, AP-HP, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France.
Carnoy S; CHRU de Lille, unité d'aphérèse, 2, avenue Oscar-Lambret, 59000 Lille, France.
Carpentier A; CHU de Liège, Cellular Therapy Lab, avenue de L'Hôpital 1, 4000 Liège, Belgique.
Fegueux N; CHU de Montpellier, service d'hématologie clinique, 191, avenue du Doyen-Giraud, 34295 Montpellier cedex 5, France.
Gibault-Joffe C; Hôpital universitaire de Genève, rue Gabrielle-Perret-Gentil 4, 1205 Genève, Suisse.
Guerout-Verite MA; EFS Bretagne, unité de thérapie cellulaire, rue Pierre-Jean-Gineste, BP 91614, Rennes cedex, France.
Huynh TNP; Institut Jules-Bordet, université Libre de Bruxelles, unité de thérapie cellulaire hématologique, service d'Hématologie, 121-125, boulevard de Waterloo, 1000 Bruxelles, Belgique.
Lewalle P; Institut Jules-Bordet, université Libre de Bruxelles, unité de thérapie cellulaire hématologique, service d'Hématologie, 121-125, boulevard de Waterloo, 1000 Bruxelles, Belgique.
Perrin A; CHRU de Lille, gestion du risque infectieux, des vigilances et infectiologie (SGRIVI), 2, avenue Oscar-Lambret, 59000 Lille, France.
Plaza-Milhe S; CHU de Montpellier, service d'hématologie clinique, 191, avenue du Doyen-Giraud, 34295 Montpellier cedex 5, France.
Bonnin A; Hôpital Saint-Antoine, AP-HP, 184, rue du Faubourg-Saint-Antoine, 75012 Paris, France.
Yakoub-Agha I; CHU de Lille, université Lille, Inserm U1286, INFINITE, 2, avenue Oscar-Lambret, 59000 Lille, France.
Contentin N; Centre Henri-Becquerel, service d'hématologie, 1, rue d'Amiens, 76038 Rouen, France.
Pokaż więcej
Transliterated Title :
Mutualisation des outils de qualité pour les cellules CAR-T : recommandations de la Société francophone de greffe de moelle et thérapie cellulaire (SFGM-TC).
Źródło :
Bulletin du cancer [Bull Cancer] 2020 Dec; Vol. 107 (12S), pp. S193-S201. Date of Electronic Publication: 2020 Nov 10.
Typ publikacji :
Journal Article; Practice Guideline
MeSH Terms :
Quality Assurance, Health Care*
Receptors, Chimeric Antigen*
Immunotherapy, Adoptive/*standards
Accreditation ; Congresses as Topic/organization & administration ; France ; Health Personnel/education ; Humans ; Immunotherapy, Adoptive/legislation & jurisprudence ; Societies, Medical
Czasopismo naukowe
Tytuł :
Influence of patient characteristics on chimeric antigen receptor T cell therapy in B-cell acute lymphoblastic leukemia.
Autorzy :
An F; Hematology Department, the Second Hospital of Anhui Medical University (SHAMU), Hefei, Anhui Province, China.; Hematologic Diseases Research Center of Anhui Medical University, Hefei, Anhui Province, China.
Wang H; Hematology Department, the Second Hospital of Anhui Medical University (SHAMU), Hefei, Anhui Province, China.; Hematologic Diseases Research Center of Anhui Medical University, Hefei, Anhui Province, China.
Liu Z; Hematologic Diseases Research Center of Anhui Medical University, Hefei, Anhui Province, China.; Sinobioway Cell Therapy Co., Ltd., Hefei, Anhui Province, China.
Wu F; Hematology Department, the Second Hospital of Anhui Medical University (SHAMU), Hefei, Anhui Province, China.; Hematologic Diseases Research Center of Anhui Medical University, Hefei, Anhui Province, China.
Zhang J; Hematology Department, the Second Hospital of Anhui Medical University (SHAMU), Hefei, Anhui Province, China.; Hematologic Diseases Research Center of Anhui Medical University, Hefei, Anhui Province, China.
Tao Q; Hematology Department, the Second Hospital of Anhui Medical University (SHAMU), Hefei, Anhui Province, China.; Hematologic Diseases Research Center of Anhui Medical University, Hefei, Anhui Province, China.
Li Y; Hematology Department, the Second Hospital of Anhui Medical University (SHAMU), Hefei, Anhui Province, China.; Hematologic Diseases Research Center of Anhui Medical University, Hefei, Anhui Province, China.
Shen Y; Hematology Department, the Second Hospital of Anhui Medical University (SHAMU), Hefei, Anhui Province, China.; Hematologic Diseases Research Center of Anhui Medical University, Hefei, Anhui Province, China.
Ruan Y; Hematology Department, the Second Hospital of Anhui Medical University (SHAMU), Hefei, Anhui Province, China.; Hematologic Diseases Research Center of Anhui Medical University, Hefei, Anhui Province, China.
Zhang Q; Hematology Department, the Second Hospital of Anhui Medical University (SHAMU), Hefei, Anhui Province, China.; Hematologic Diseases Research Center of Anhui Medical University, Hefei, Anhui Province, China.
Pan Y; Hematology Department, the Second Hospital of Anhui Medical University (SHAMU), Hefei, Anhui Province, China.; Hematologic Diseases Research Center of Anhui Medical University, Hefei, Anhui Province, China.
Zhu W; Hematology Department, the Second Hospital of Anhui Medical University (SHAMU), Hefei, Anhui Province, China.; Hematologic Diseases Research Center of Anhui Medical University, Hefei, Anhui Province, China.
Qin H; Hematology Department, the Second Hospital of Anhui Medical University (SHAMU), Hefei, Anhui Province, China.; Hematologic Diseases Research Center of Anhui Medical University, Hefei, Anhui Province, China.
Wang Y; Hematology Department, the Second Hospital of Anhui Medical University (SHAMU), Hefei, Anhui Province, China.; Hematologic Diseases Research Center of Anhui Medical University, Hefei, Anhui Province, China.
Fu Y; Sinobioway Cell Therapy Co., Ltd., Hefei, Anhui Province, China.
Feng Z; Key Laboratory of Antibody Technique of National Health Commission, Nanjing Medical University, Nanjing, Jiangsu Province, China. .; Jiangsu Key Lab. of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, Jiangsu Province, China. .
Zhai Z; Hematology Department, the Second Hospital of Anhui Medical University (SHAMU), Hefei, Anhui Province, China. .; Hematologic Diseases Research Center of Anhui Medical University, Hefei, Anhui Province, China. .
Pokaż więcej
Źródło :
Nature communications [Nat Commun] 2020 Nov 23; Vol. 11 (1), pp. 5928. Date of Electronic Publication: 2020 Nov 23.
Typ publikacji :
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Immunotherapy, Adoptive*
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/*pathology
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/*therapy
T-Lymphocytes/*transplantation
Adolescent ; Adult ; Aged ; Child ; Child, Preschool ; Disease-Free Survival ; Female ; Humans ; Male ; Middle Aged ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/mortality ; Receptors, Antigen, T-Cell/immunology ; Recurrence ; Remission Induction ; Risk Factors ; Safety ; Survival Rate ; T-Lymphocytes/immunology ; Young Adult
Czasopismo naukowe
Tytuł :
The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy.
Autorzy :
Ljungman P; Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Stockholm, Sweden. .; Division of Hematology, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden. .
Mikulska M; Division of Infectious Diseases, University of Genoa and Ospedale Policlinico San Martino, Genova, Italy.
de la Camara R; Department of Hematology, Hospital de la Princesa, Madrid, Spain.
Basak GW; Department of Hematology, Oncology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.
Chabannon C; Institut Paoli Calmettes & Inserm CBT-1409, Centres d'Investigations Cliniques en Biothérapies, Marseille, France.
Corbacioglu S; Pediatric Hematology, Oncology and Stem Cell Transplantation Department, University of Regensburg, Regensburg, Germany.
Duarte R; Servicio de Hematologia y Hemoterapia, Hospital Universitario Puerta de Hierro, Madrid, Spain.
Dolstra H; Laboratory of Hematology, Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.
Lankester AC; Willem-Alexander Children's Hospital, Department of Pediatrics, Leiden University Medical Centre Leiden, Leiden, the Netherlands.
Mohty M; Department of Hematology, Hospital Saint Antoine, Paris, France.
Montoto S; St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
Murray J; The Christie NHS Foundation Trust, Manchester, UK.
Peffault de Latour R; BMT Unit, Department of Hematology, Hospital St. Louis, Paris, France.
Snowden JA; Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Yakoub-Agha I; CHU de Lille, Univ Lille, INSERM, U1285, Lille, France.
Verhoeven B; Foundation Hematon, Utrecht, the Netherlands.
Kröger N; Department of Stem cell Transplantation, University Hospital Eppendorf, Hamburg, Germany.
Styczynski J; Pediatric Hematology and Oncology, University Hospital, Collegium Medicum, Nicolaus Copernicus University Torun, Bydgoszcz, Poland.
Pokaż więcej
Corporate Authors :
European Society for Blood and Marrow Transplantation
Źródło :
Bone marrow transplantation [Bone Marrow Transplant] 2020 Nov; Vol. 55 (11), pp. 2071-2076. Date of Electronic Publication: 2020 May 13.
Typ publikacji :
Journal Article; Practice Guideline; Review
MeSH Terms :
Betacoronavirus*
Coronavirus Infections*/diagnosis
Coronavirus Infections*/epidemiology
Coronavirus Infections*/prevention & control
Hematopoietic Stem Cell Transplantation*/methods
Hematopoietic Stem Cell Transplantation*/statistics & numerical data
Immunotherapy, Adoptive*
Pandemics*/prevention & control
Pneumonia, Viral*/diagnosis
Pneumonia, Viral*/epidemiology
Pneumonia, Viral*/prevention & control
Delivery of Health Care/*standards
Infection Control/*standards
Accreditation/organization & administration ; Allografts ; COVID-19 ; COVID-19 Testing ; Clinical Laboratory Techniques ; Continuity of Patient Care ; Cross Infection/prevention & control ; Europe ; Health Personnel ; Humans ; Immunocompromised Host ; Infectious Disease Transmission, Patient-to-Professional/prevention & control ; Infectious Disease Transmission, Professional-to-Patient/prevention & control ; Office Visits ; Procedures and Techniques Utilization ; SARS-CoV-2 ; Telemedicine ; Tissue Donors ; Transplant Recipients ; Transplantation, Autologous ; Visitors to Patients
Czasopismo naukowe
Tytuł :
Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center.
Autorzy :
Sesques P; Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.; Claude Bernard Lyon 1 University, Lyon, France.
Ferrant E; Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
Safar V; Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
Wallet F; Department of Critical Care, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
Tordo J; Department of Nuclear Medicine, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
Dhomps A; Department of Nuclear Medicine, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
Karlin L; Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
Brisou G; Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.; Claude Bernard Lyon 1 University, Lyon, France.
Vercasson M; Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
Hospital-Gustem C; Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
Schwiertz V; Department of Pharmacy, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
Ranchon F; Claude Bernard Lyon 1 University, Lyon, France.; Department of Pharmacy, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
Rioufol C; Claude Bernard Lyon 1 University, Lyon, France.; Department of Pharmacy, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
Choquet M; Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
Sujobert P; Claude Bernard Lyon 1 University, Lyon, France.; Department of Hematology Laboratory, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.; Lyon Cancer Research Center, INSERM U1052 and CNRS UMR5286, Lyon, France.
Ghergus D; Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
Bouafia F; Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
Golfier C; Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.; Claude Bernard Lyon 1 University, Lyon, France.
Lequeu H; Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
Lazareth A; Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
Novelli S; Lyon Cancer Research Center, INSERM U1052 and CNRS UMR5286, Lyon, France.
Devic P; Department of Neurology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
Traverse Glehen A; Claude Bernard Lyon 1 University, Lyon, France.; Lyon Cancer Research Center, INSERM U1052 and CNRS UMR5286, Lyon, France.; Department of Pathology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.
Viel S; Claude Bernard Lyon 1 University, Lyon, France.; Department of Biological Immunology, Hospices Civils de Lyon, Lyon Sud Hospital, Lyon, France.; International Center for Research in Infectious Diseases, INSERM U1111 and CNRS UMR5308, Lyon, France.
Venet F; Claude Bernard Lyon 1 University, Lyon, France.; Department of Clinical Immunology, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France.
Mialou V; Department of Biology and Therapy, Etablissement Français du Sang Auvergne-Rhône-Alpes, Decines-Charpieu, France.
Hequet O; Department of Biology and Therapy, Etablissement Français du Sang Auvergne-Rhône-Alpes, Decines-Charpieu, France.
Chauchet A; Department of Hematology, Besançon University Hospital, Besançon, France.
Arkam Y; Department of Hematology, Hopital Emile Muller, Mulhouse, France.
Nicolas-Virelizier E; Department of Hematology, Centre Léon Bérard, Lyon, France.
Peyrade F; Department of Hematology, Centre Antoine Lacassagne, Nice, France.
Cavalieri D; Department of Hematology, Clermont Ferrand University Hospital, Clermont Ferrand, France.
Ader F; Department of Infectious Disease, Hospices Civils de Lyon, Croix Rousse Hospital, Lyon, France.
Ghesquières H; Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.; Claude Bernard Lyon 1 University, Lyon, France.; Lyon Cancer Research Center, INSERM U1052 and CNRS UMR5286, Lyon, France.
Salles G; Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.; Claude Bernard Lyon 1 University, Lyon, France.; Lyon Cancer Research Center, INSERM U1052 and CNRS UMR5286, Lyon, France.
Bachy E; Department of Hematology, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.; Claude Bernard Lyon 1 University, Lyon, France.; Lyon Cancer Research Center, INSERM U1052 and CNRS UMR5286, Lyon, France.
Pokaż więcej
Źródło :
American journal of hematology [Am J Hematol] 2020 Nov; Vol. 95 (11), pp. 1324-1333. Date of Electronic Publication: 2020 Aug 25.
Typ publikacji :
Clinical Trial; Journal Article
MeSH Terms :
Immunotherapy, Adoptive*
Lymphoma, Large B-Cell, Diffuse*/blood
Lymphoma, Large B-Cell, Diffuse*/mortality
Lymphoma, Large B-Cell, Diffuse*/therapy
Antigens, CD19/*blood
Antigens, Neoplasm/*blood
Adult ; Aged ; Disease-Free Survival ; Female ; France/epidemiology ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Survival Rate
Czasopismo naukowe
Tytuł :
[Genetically modified regulatory T cells: therapeutic concepts and regulatory aspects].
Autorzy :
Sebe A; Abteilung Medizinische Biotechnologie, Paul-Ehrlich-Institut, Paul-Ehrlich-Str. 51-59, 63225, Langen, Deutschland.
Anliker B; Abteilung Medizinische Biotechnologie, Paul-Ehrlich-Institut, Paul-Ehrlich-Str. 51-59, 63225, Langen, Deutschland.
Rau J; Abteilung Medizinische Biotechnologie, Paul-Ehrlich-Institut, Paul-Ehrlich-Str. 51-59, 63225, Langen, Deutschland.
Renner M; Abteilung Medizinische Biotechnologie, Paul-Ehrlich-Institut, Paul-Ehrlich-Str. 51-59, 63225, Langen, Deutschland. .
Pokaż więcej
Transliterated Title :
Genetisch modifizierte regulatorische T-Zellen: Therapiekonzepte und ihr regulatorischer Rahmen.
Źródło :
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz [Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz] 2020 Nov; Vol. 63 (11), pp. 1403-1411. Date of Electronic Publication: 2020 Oct 16.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Immunotherapy, Adoptive*
T-Lymphocytes, Regulatory*
Germany ; Humans
Czasopismo naukowe
Tytuł :
Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infection.
Autorzy :
Yang C; Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, Zhejiang, China.; Institute of Hematology, Zhejiang University, Hangzhou, 310003, Zhejiang, China.
Xie M; Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, Zhejiang, China.; Institute of Hematology, Zhejiang University, Hangzhou, 310003, Zhejiang, China.
Zhang K; Institute of Hematology, Zhejiang University, Hangzhou, 310003, Zhejiang, China.
Liu H; Department of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310009, Zhejiang, China.
Liang A; Department of Hematology, Tongji Hospital of Tongji University, Shanghai, 200065, China. .
Young KH; Hematopathology Division and Department of Pathology, Duke University School of Medicine, Duke University Medical Center and Cancer Institute, Durham, NC, 27710, USA. .
Qian W; Institute of Hematology, Zhejiang University, Hangzhou, 310003, Zhejiang, China. .; Department of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310009, Zhejiang, China. .
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2020 Nov; Vol. 34 (11), pp. 3055-3059. Date of Electronic Publication: 2020 Jun 12.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Hepatitis B virus*/physiology
Virus Activation*/immunology
Hepatitis B, Chronic/*complications
Hepatitis B, Chronic/*virology
Immunotherapy, Adoptive/*adverse effects
Lymphoma, Large B-Cell, Diffuse/*complications
Antigens, CD19/immunology ; Hepatitis B, Chronic/diagnosis ; Humans ; Immunosuppressive Agents/adverse effects ; Immunosuppressive Agents/therapeutic use ; Immunotherapy, Adoptive/methods ; Lymphoma, Large B-Cell, Diffuse/therapy ; Viral Load
Raport
Tytuł :
Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.
Autorzy :
Anagnostou T; Department of Medicine, Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.
Riaz IB; Division of Haematology, Mayo Clinic, Rochester, MN, USA.
Hashmi SK; Division of Haematology, Mayo Clinic, Rochester, MN, USA; Oncology Centre, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
Murad MH; Evidence-Based Practice Center, Mayo Clinic, Rochester, MN, USA.
Kenderian SS; Division of Haematology, Mayo Clinic, Rochester, MN, USA; Department of Immunology, Mayo Clinic, Rochester, MN, USA; T-Cell Engineering, Mayo Clinic, Rochester, MN, USA; Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA. Electronic address: .
Pokaż więcej
Źródło :
The Lancet. Haematology [Lancet Haematol] 2020 Nov; Vol. 7 (11), pp. e816-e826.
Typ publikacji :
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Immunotherapy, Adoptive*/adverse effects
Antigens, CD19/*immunology
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*therapy
Cytokine Release Syndrome/etiology ; Humans ; Neoplasm, Residual ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality ; Progression-Free Survival ; Receptors, Chimeric Antigen/therapeutic use ; Remission Induction ; Transplantation, Autologous
Czasopismo naukowe
Tytuł :
Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo.
Autorzy :
Maldini CR; Department of Microbiology, Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Claiborne DT; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Okawa K; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Chen T; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Dopkin DL; Department of Pathology & Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Shan X; Department of Pathology & Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Power KA; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Trifonova RT; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Krupp K; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Phelps M; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Vrbanac VD; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.; Human Immune System Mouse Program, Massachusetts General Hospital, Boston, MA, USA.
Tanno S; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.; Human Immune System Mouse Program, Massachusetts General Hospital, Boston, MA, USA.
Bateson T; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Leslie GJ; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Hoxie JA; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Boutwell CL; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Riley JL; Department of Microbiology, Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. .
Allen TM; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA. .
Pokaż więcej
Źródło :
Nature medicine [Nat Med] 2020 Nov; Vol. 26 (11), pp. 1776-1787. Date of Electronic Publication: 2020 Aug 31.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Immunotherapy, Adoptive*
CD4 Antigens/*immunology
HIV Infections/*therapy
Receptors, Chimeric Antigen/*immunology
Animals ; Antibodies, Monoclonal, Humanized/immunology ; Antibodies, Monoclonal, Humanized/pharmacology ; Bone Marrow/immunology ; Bone Marrow/virology ; CD3 Complex/antagonists & inhibitors ; CD4 Antigens/administration & dosage ; Gene Expression Regulation/immunology ; HIV Envelope Protein gp41/antagonists & inhibitors ; HIV Envelope Protein gp41/immunology ; HIV Infections/immunology ; HIV Infections/pathology ; HIV Infections/virology ; HIV-1/immunology ; HIV-1/pathogenicity ; Humans ; Liver/immunology ; Liver/virology ; Mice ; Peptide Fragments/antagonists & inhibitors ; Peptide Fragments/immunology ; Protein Domains/immunology ; Receptors, CXCR4/antagonists & inhibitors ; Receptors, CXCR4/immunology ; Receptors, Chimeric Antigen/administration & dosage ; T-Lymphocytes/immunology ; Thymus Gland/immunology ; Thymus Gland/virology ; Tumor Necrosis Factor Receptor Superfamily, Member 9/antagonists & inhibitors
Czasopismo naukowe
Tytuł :
Long: molecular tracking of CML with bilineal inv(16) myeloid and del(9) lymphoid blast crisis and durable response to CD19-directed CAR-T therapy.
Autorzy :
Venkataraman V; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Casey KS; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Onozato M; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
Cin PD; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Nardi V; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
Amrein PC; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Bergeron MK; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Brunner AM; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Fathi AT; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Foster JE; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Moran J; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Graubert TA; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Hock H; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Hunnewell C; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Frigault MJ; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
McAfee S; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Hobbs GS; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. .
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2020 Nov; Vol. 34 (11), pp. 3050-3054. Date of Electronic Publication: 2020 Jul 16.
Typ publikacji :
Case Reports; Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antigens, CD19*/immunology
Immunotherapy, Adoptive*/methods
Blast Crisis/*genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*therapy
Oncogene Proteins, Fusion/*genetics
Blast Crisis/pathology ; Disease Management ; Disease Susceptibility ; Humans ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/mortality ; Male ; Receptors, Chimeric Antigen/genetics ; Receptors, Chimeric Antigen/immunology ; Treatment Outcome ; Young Adult
Raport
Tytuł :
Synergistic effect of ibrutinib and CD19 CAR-T cells on Raji cells in vivo and in vitro.
Autorzy :
Liu M; The First Central Clinical College of Tianjin Medical University, Tianjin, China.
Wang X; Institute of Developmental Biology and Molecular Medicine, Fudan University, Shanghai, China.
Li Z; The First Central Clinical College of Tianjin Medical University, Tianjin, China.
Zhang R; Department of Hematology, Tianjin First Central Hospital, Tianjin, China.
Mu J; Department of Hematology, Tianjin First Central Hospital, Tianjin, China.
Jiang Y; Department of Hematology, Tianjin First Central Hospital, Tianjin, China.
Deng Q; Department of Hematology, Tianjin First Central Hospital, Tianjin, China.
Sun L; Institute of Developmental Biology and Molecular Medicine, Fudan University, Shanghai, China.
Pokaż więcej
Źródło :
Cancer science [Cancer Sci] 2020 Nov; Vol. 111 (11), pp. 4051-4060. Date of Electronic Publication: 2020 Sep 15.
Typ publikacji :
Journal Article
MeSH Terms :
Immunotherapy, Adoptive*/methods
Adenine/*analogs & derivatives
Antigens, CD19/*immunology
Piperidines/*pharmacology
Protein Kinase Inhibitors/*pharmacology
T-Lymphocytes/*immunology
T-Lymphocytes/*metabolism
Adenine/pharmacology ; Adult ; Aged ; Animals ; Biomarkers, Tumor ; Cell Line, Tumor ; Combined Modality Therapy ; Disease Models, Animal ; Female ; Humans ; Immunophenotyping ; Lymphoma, Large B-Cell, Diffuse/genetics ; Lymphoma, Large B-Cell, Diffuse/immunology ; Lymphoma, Large B-Cell, Diffuse/pathology ; Lymphoma, Large B-Cell, Diffuse/therapy ; Male ; Mice ; Middle Aged ; Neoplasm Staging ; Receptors, Antigen, T-Cell/genetics ; Receptors, Antigen, T-Cell/metabolism ; STAT3 Transcription Factor/metabolism ; Treatment Outcome ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection.
Autorzy :
Wang Y; Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.; Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.; Jiangsu Key Laboratory of Bone Marrow Stem Cells, Xuzhou, Jiangsu, China.
Liu Y; Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.; Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.; Jiangsu Key Laboratory of Bone Marrow Stem Cells, Xuzhou, Jiangsu, China.
Tan X; Medical Center of Hematology, Xinqiao Hospital, Army Medical University, Chongqing, China.
Pan B; Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.; Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.; Jiangsu Key Laboratory of Bone Marrow Stem Cells, Xuzhou, Jiangsu, China.
Ge J; Department of Hematology, The First Affiliated Hospital of Anhui Medical University, He Fei, An Hui, China.
Qi K; Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.; Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.; Jiangsu Key Laboratory of Bone Marrow Stem Cells, Xuzhou, Jiangsu, China.
Cheng H; Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.; Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.; Jiangsu Key Laboratory of Bone Marrow Stem Cells, Xuzhou, Jiangsu, China.
Cao J; Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.; Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.; Jiangsu Key Laboratory of Bone Marrow Stem Cells, Xuzhou, Jiangsu, China.
Shi M; Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.; Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Yan Z; Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.; Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.; Jiangsu Key Laboratory of Bone Marrow Stem Cells, Xuzhou, Jiangsu, China.
Qiao J; Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.; Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.; Jiangsu Key Laboratory of Bone Marrow Stem Cells, Xuzhou, Jiangsu, China.
Jing G; iCARTAB biomedical co. LTD, Suzhou, Jiangsu, China.
Wang X; Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.; Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.; Jiangsu Key Laboratory of Bone Marrow Stem Cells, Xuzhou, Jiangsu, China.
Sang W; Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.; Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.; Jiangsu Key Laboratory of Bone Marrow Stem Cells, Xuzhou, Jiangsu, China.
Xia R; Department of Hematology, The First Affiliated Hospital of Anhui Medical University, He Fei, An Hui, China.
Zhang X; Medical Center of Hematology, Xinqiao Hospital, Army Medical University, Chongqing, China.
Li Z; Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.; Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.; Jiangsu Key Laboratory of Bone Marrow Stem Cells, Xuzhou, Jiangsu, China.
Gale RP; Department of Immunology and Inflammation, Centre for Haematology Research, Imperial College London, London, UK.
Zheng J; Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China. .; Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. .
Zhu F; Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China. .; Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. .; Jiangsu Key Laboratory of Bone Marrow Stem Cells, Xuzhou, Jiangsu, China. .
Xu K; Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China. .; Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. .; Jiangsu Key Laboratory of Bone Marrow Stem Cells, Xuzhou, Jiangsu, China. .
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2020 Oct; Vol. 34 (10), pp. 2704-2707. Date of Electronic Publication: 2020 Jun 27.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Immunotherapy, Adoptive*/adverse effects
Immunotherapy, Adoptive*/methods
Hepatitis B/*immunology
Hepatitis B/*therapy
Leukemia, B-Cell/*immunology
Leukemia, B-Cell/*therapy
Lymphoma, B-Cell/*immunology
Lymphoma, B-Cell/*therapy
Adolescent ; Adult ; Aged ; Child ; Child, Preschool ; Female ; Hepatitis B/diagnosis ; Hepatitis B/virology ; Humans ; Liver Function Tests ; Lymphocyte Count ; Lymphoma, B-Cell/diagnosis ; Male ; Middle Aged ; Neoplasm Staging ; Receptors, Chimeric Antigen/immunology ; T-Lymphocytes/immunology ; T-Lymphocytes/metabolism ; Treatment Outcome ; Viral Load ; Young Adult
Czasopismo naukowe
Tytuł :
The efficacy and safety of CAR-T cell therapy in patients with refractory ALL and concomitant HBV infection.
Autorzy :
Lai P; Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong, PR China.; State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Guangzhou, 510530, Guangdong, PR China.; Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, 510530, Guangzhou, PR China.
Chen X; Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong, PR China.
Qin L; State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Guangzhou, 510530, Guangdong, PR China.
Jiang Z; State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Guangzhou, 510530, Guangdong, PR China.
Luo C; Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong, PR China.
Huang X; Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong, PR China.
Wu S; Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong, PR China.
Ling W; Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong, PR China.
Wang Y; Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong, PR China.
Wang J; Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong, PR China.
Deng C; Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong, PR China.
Huang L; Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong, PR China.
Zeng L; Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong, PR China.
Lu Z; Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong, PR China.
Zhong L; Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong, PR China.
Liao P; Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong, PR China.
Li M; Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong, PR China.
Chen D; State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Guangzhou, 510530, Guangdong, PR China.
Geng S; Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong, PR China.
Wu P; Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong, PR China.
Tang Z; Guangdong Zhaotai InVivo Biomedicine Co. Ltd, 510000, Guangzhou, PR China.
Pei D; State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Guangzhou, 510530, Guangdong, PR China.; Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, 510530, Guangzhou, PR China.
Du X; Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong, PR China. .
Li P; State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Guangzhou, 510530, Guangdong, PR China. .; Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, 510530, Guangzhou, PR China. .
Weng J; Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong, PR China. .
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2020 Oct; Vol. 34 (10), pp. 2790-2793. Date of Electronic Publication: 2020 Jul 06.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Hepatitis B virus*/immunology
Immunotherapy, Adoptive*/adverse effects
Immunotherapy, Adoptive*/methods
Hepatitis B/*complications
Hepatitis B/*virology
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*complications
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*therapy
Animals ; Disease Models, Animal ; Female ; Hepatitis B/diagnosis ; Hepatitis B/immunology ; Humans ; Male ; Mice ; Middle Aged ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/immunology ; Receptors, Antigen, T-Cell ; Receptors, Chimeric Antigen ; T-Lymphocytes/immunology ; T-Lymphocytes/metabolism ; Treatment Outcome ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Opportunities and challenges associated with the evaluation of chimeric antigen receptor T cells in real-life.
Autorzy :
McGrath E; EBMT Executive Office, Barcelona.; Legal Regulatory Affairs Committee (LRAC) of EBMT, Barcelona, Spain.
Chabannon C; Legal Regulatory Affairs Committee (LRAC) of EBMT, Barcelona, Spain.; Institut Paoli-Calmettes, Centre de Lutte Contre le Cancer, Université d'Aix-Marseille, INSERM CBT 1409, Centre d'Investigations Cliniques en Biothérapie, Marseille, France.; Cellular Therapy & Immunobiology Working Party (CTIWP).
Terwel S; EBMT GoCART, Leiden, The Netherlands.
Bonini C; Cellular Therapy & Immunobiology Working Party (CTIWP).; Università Vita-Salute San Raffaele, Milan, Italy.
Kuball J; Legal Regulatory Affairs Committee (LRAC) of EBMT, Barcelona, Spain.; Cellular Therapy & Immunobiology Working Party (CTIWP).; Department of Hematology, Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Pokaż więcej
Źródło :
Current opinion in oncology [Curr Opin Oncol] 2020 Sep; Vol. 32 (5), pp. 427-433.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Immunotherapy, Adoptive/*methods
Receptors, Antigen, T-Cell/*immunology
Receptors, Chimeric Antigen/*immunology
Clinical Trials, Phase II as Topic ; European Union ; Government Agencies ; Humans ; Immunotherapy, Adoptive/adverse effects ; Immunotherapy, Adoptive/statistics & numerical data ; Registries ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Metabolic optimization of adoptive T cell transfer cancer immunotherapy: A historical overview.
Autorzy :
Forsdyke DR; Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada.
Pokaż więcej
Źródło :
Scandinavian journal of immunology [Scand J Immunol] 2020 Sep; Vol. 92 (3), pp. e12929. Date of Electronic Publication: 2020 Jul 24.
Typ publikacji :
Journal Article
MeSH Terms :
Energy Metabolism*
Immunotherapy, Adoptive*/adverse effects
Immunotherapy, Adoptive*/methods
Neoplasms/*immunology
Neoplasms/*therapy
T-Lymphocytes/*immunology
T-Lymphocytes/*metabolism
Animals ; Biomarkers ; Cellular Reprogramming ; Culture Media ; Gene Expression Regulation ; Humans ; Lymphocyte Activation/genetics ; Lymphocyte Activation/immunology ; Neoplasms/genetics ; Neoplasms/metabolism ; Primary Cell Culture ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Hematopoietic Cell Transplantation and Adoptive Cell Therapy in Peripheral T Cell Lymphoma.
Autorzy :
Rogers AM; Department of Internal Medicine, Division of Hematology, James Comprehensive Cancer Center, The Ohio State University, 320 West Tenth Avenue, Columbus, OH, 43210, USA.
Brammer JE; Department of Internal Medicine, Division of Hematology, James Comprehensive Cancer Center, The Ohio State University, 320 West Tenth Avenue, Columbus, OH, 43210, USA. .
Pokaż więcej
Źródło :
Current hematologic malignancy reports [Curr Hematol Malig Rep] 2020 Aug; Vol. 15 (4), pp. 316-332.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Review
MeSH Terms :
Hematopoietic Stem Cell Transplantation*/adverse effects
Hematopoietic Stem Cell Transplantation*/mortality
Immunotherapy, Adoptive*/adverse effects
Immunotherapy, Adoptive*/mortality
Lymphoma, T-Cell, Peripheral/*therapy
Receptors, Chimeric Antigen/*immunology
T-Lymphocytes/*transplantation
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Brentuximab Vedotin/therapeutic use ; Histone Deacetylase Inhibitors/therapeutic use ; Humans ; Induction Chemotherapy ; Lymphoma, T-Cell, Peripheral/genetics ; Lymphoma, T-Cell, Peripheral/immunology ; Lymphoma, T-Cell, Peripheral/mortality ; Salvage Therapy ; T-Lymphocytes/immunology ; Transplantation, Autologous ; Treatment Outcome
Czasopismo naukowe
Tytuł :
CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges.
Autorzy :
Hu Y; Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China; Institute of Hematology, Zhejiang University, Hangzhou, China. Electronic address: .
Tan Su Yin E; Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China; Institute of Hematology, Zhejiang University, Hangzhou, China. Electronic address: .
Yang Y; Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China; Institute of Hematology, Zhejiang University, Hangzhou, China. Electronic address: .
Wu H; Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China; Institute of Hematology, Zhejiang University, Hangzhou, China. Electronic address: .
Wei G; Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China; Institute of Hematology, Zhejiang University, Hangzhou, China. Electronic address: .
Su J; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Department of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China. Electronic address: .
Cui Q; Department of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Electronic address: .
Jin A; Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China; Institute of Hematology, Zhejiang University, Hangzhou, China. Electronic address: .
Yang L; Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China; Institute of Hematology, Zhejiang University, Hangzhou, China. Electronic address: .
Fu S; Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China; Institute of Hematology, Zhejiang University, Hangzhou, China. Electronic address: .
Zhou J; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Electronic address: .
Qiu L; State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China. Electronic address: .
Zhang X; Medical Center of Hematology, Xinqiao Hospital, Army Medical University, Chongqing, China. Electronic address: .
Liang A; Department of Hematology, Shanghai Tongji Hospital, Shanghai, China. Electronic address: .
Jing H; Department of Hematology, Peking University Third Hospital, Beijing, China. Electronic address: .
Li Y; Department of Hematology, Zhujiang Hospital of Southern Medical University, Guangzhou, China. Electronic address: .
Blaise D; Transplant and Cellular Immunotherapy Programs, Department of Hematology, Institut Paoli-Calmettes, Aix Marseille Univ, CNRS, INSERM, CRCM, Marseille, France. Electronic address: .
Mohty M; Sorbonne University, Department of Hematology, Hôpital Saint Antoine, Paris, France; INSERM UMRs 938, EBMT Paris Study Office/CEREST-TC, Paris, France. Electronic address: .
Nagler A; Hematology and Bone Marrow Transplantation Division, Chaim Sheba Medical Center, Tel-Hashomer, Israel. Electronic address: .
Huang H; Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China; Institute of Hematology, Zhejiang University, Hangzhou, China. Electronic address: .
Pokaż więcej
Źródło :
Current research in translational medicine [Curr Res Transl Med] 2020 Aug; Vol. 68 (3), pp. 111-118. Date of Electronic Publication: 2020 Jun 28.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Immunotherapy, Adoptive*/methods
Immunotherapy, Adoptive*/trends
Coronavirus Infections/*prevention & control
Delivery of Health Care/*organization & administration
Hematologic Neoplasms/*therapy
Infection Control/*organization & administration
Pandemics/*prevention & control
Pneumonia, Viral/*prevention & control
Receptors, Antigen, T-Cell/*immunology
Betacoronavirus/physiology ; COVID-19 ; Coronavirus Infections/epidemiology ; Delivery of Health Care/methods ; Delivery of Health Care/standards ; Delivery of Health Care/trends ; Hematologic Neoplasms/epidemiology ; Humans ; Infection Control/methods ; Infection Control/standards ; Infection Control/trends ; Pneumonia, Viral/epidemiology ; Preventive Health Services/methods ; Preventive Health Services/organization & administration ; Preventive Health Services/standards ; Preventive Health Services/trends ; SARS-CoV-2
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies